Rakuten Medical, Inc. is revolutionizing oncology with its proprietary Alluminox™ photoimmunotherapy platform, a precision-based cancer treatment that fuses tumor targeting antibody dye conjugates with localized light activation to induce rapid, selective cancer cell death. Its lead candidate, ASP 1929 (marketed as Akalux® in Japan), gained conditional approval in September 2020—alongside the BioBlade® laser system—for unresectable or recurrent head and neck cancer. Beyond its therapeutic promise, ASP 1929 holds key regulatory milestones, including FDA Fast Track and Japanese Sakigake designations. Rakuten Medical is advancing its pipeline globally, with ongoing Phase 3 trials and combination studies pairing ASP 1929 with immune checkpoint inhibitors.